Pfizer harnesses COVID fluctuations to clinch Q4 gains as RSV vaccine sales plummet
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” | The company benefited from higher-than-expected sales of COVID vaccine Comirnaty and antiviral Paxlovid,
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
1don MSN
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...
Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.
Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback